HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

January 29, 2024

https://www.globenewswire.com/news-release/2024/01/29/2818871/0/en/HOOKIPA-Pharma-Provides-Update-on-Business-Priorities-and-Oncology-Partnership-Programs.html

NEW YORK and VIENNA, Austria, Jan. 29, 2024 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company will focus its resources in two strategic areas: (1) prioritize the clinical development of a randomized trial for its HB-200 program in human papillomavirus 16 positive (HPV16+) head and neck squamous cell carcinoma (HNSCC) and (2) its two Gilead-partnered infectious disease cure programs for hepatitis B and human immunodeficiency virus.

Read more at globenewswire.com

Related news for (HOOK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.